Page last updated: 2024-12-07

3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(N-prolylamine)-2-oxo-1-pyrrolidineacetamide: structure given in first source; RN given refers to (S-(R*,R*))-isomer; RN for cpd without isomeric designation not available 12/94; MSH Release-inhibiting hormone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129409
MeSH IDM0184958

Synonyms (7)

Synonym
(2s)-n-[(3s)-1-(2-amino-2-oxoethyl)-2-oxopyrrolidin-3-yl]pyrrolidine-2-carboxamide
106732-52-9
(s-(r*,r*))-2-oxo-3-((2-pyrrolidinylcarbonyl)amino)-1-pyrrolidineacetamide
1-pyrrolidineacetamide, 2-oxo-3-((2-pyrrolidinylcarbonyl)amino)-, (s-(r*,r*))-
3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide
2-oxo-3(r)-((2(s)-pyrrolidinylcarbonyl)amino)-1-pyrrolidineacetamide
DTXSID40147746

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" To advance this newly developed allosteric drug from the preclinical to clinical stage, this study examines the pharmacokinetic behavior and toxicological profile of PAOPA."( Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia.
Basu, D; Johnson, RL; Kwiecien, JM; Mishra, RK; Tan, ML, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (35.71)18.2507
2000's3 (21.43)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]